Prokaryotics Announces the Promotion of Holly Sutterlin, PhD, to Chief Operating Officer

Union, NJ – June 1, 2022 -- Prokaryotics, Inc., a privately-held biopharmaceutical company engaged in the discovery and development of mechanistically novel anti-infective drugs, announced today the promotion of Dr. Holly Sutterlin from the dual roles of Director of Microbial Genetics and Director of Operations to Chief Operating Officer.

Dr. Sutterlin has been central to the founding and continued growth of Prokaryotics. Her scientific and operational excellence is critically important to our future success, and her promotion to COO underscores our confidence in her as we continue our mission.
-- Terry Roemer, Ph.D., Founder and Chief Scientific Officer of Prokaryotics Inc.

Holly is an inspiring leader and a terrific scientist. Her outstanding organizational skills have been essential in building this company, and we are privileged to have her as an officer and a scientific colleague.
-- Sherman T Waddell, Ph.D., Founder and Vice President of Chemistry of Prokaryotics Inc.

About Prokaryotics, Inc.
Prokaryotics, Inc. is a biopharmaceutical company founded on Merck & Co out-licensed antibiotic assets under development to treat life-threatening AMR bacterial infections. Prokaryotics leverages its deep expertise in bacterial physiology, medicinal chemistry, collaborative spirit, and scientific passion to discover and develop new classes of antibiotics targeting outer membrane biogenesis – the fundamental armor erected by bacteria to naturally withstand the effects of antibiotics and innate immunity.

Media Contact:
Holly Sutterlin
908 737-1922 x124